Lenvatinib treatment for advanced bone or soft tissue sarcoma
Part of Bones, joints & muscles, Cancer clinical trials.
This trial tests lenvatinib to shrink or control advanced bone or soft tissue sarcoma that can’t be safely treated with surgery. You may be eligible if your cancer has measurable spots and you’ve had specific prior drug treatments without a durable response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 10–70 (any sex).
- Your performance status is 0–1 (or amputation may allow a slightly higher score), and your expected survival is at least 3 months.
- Your sarcoma is advanced or has spread (distant metastases) and your doctor believes surgery isn’t suitable.
- You have measurable tumor spots on scans that can be followed (meet RECIST 1.1).
- Any prior treatment side effects are mostly gone by the first dose day (grade 0–1), except hair loss if your doctor feels it’s safe.
- You meet key safety lab and heart/thyroid requirements, and you’re not dealing with certain serious infections or uncontrolled medical problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the drug lenvatinib can shrink or slow advanced parathyroid cancer that cannot be removed by surgery. Lenvatinib is a targeted therapy that blocks blood vessel growth to tumors, which may help control the disease.
This study tests whether combining two targeted drugs, everolimus and lenvatinib, is better than everolimus alone for people with advanced bone sarcoma. These drugs work by blocking signals that help cancer cells grow and by cutting off the blood supply to tumors.
This study tests a combination of two drugs (anlotinib and bempegaldesleukin) plus standard chemotherapy and radiation for people with advanced soft tissue sarcoma that has spread or can't be removed. The goal is to see if this combination helps shrink tumors and control the cancer.
This trial tests a combination of two drugs, lenvatinib (a targeted therapy that stops blood vessel growth to tumors) and a PD-1 inhibitor (an immunotherapy that helps your immune system fight cancer), in people with advanced solid tumors that have a specific genetic change called 11q13 amplification. The goal is to see if this combination can shrink or control tumors that haven't responded to other treatments.
This trial tests a combination of two drugs (pembrolizumab and lenvatinib) for people with a rare skin cancer called cutaneous angiosarcoma that cannot be removed by surgery. The goal is to see if the combination shrinks the tumor or slows its growth.
This Phase 3 study tests two anti-cancer medicines (anlotinib and catequentinib) for people with certain advanced soft-tissue sarcomas, including alveolar soft part sarcoma, synovial sarcoma, and leiomyosarcoma. It is designed for tumors that cannot be removed and that have either grown despite treatment or no longer respond to standard options.
Hear when a new Effectiveness trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.